US District Court rules in favour of Amgen in Repatha patents cases

The US District Court in Delaware has granted Amgen's request for a permanent injunction prohibiting Sanofi and Regeneron from infringing two patents that Amgen holds for Repatha (evolocumab) by manufacturing, using, selling or offering alirocumab for sale in the US. The injunction will not take effect immediately as the court has delayed its imposition for 30 days to allow defendants the opportunity to seek expedited review of this decision. 

The judge’s decision follows a jury verdict in March 2016 in Amgen's favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to proprotein convertase